[Correspondence] Safety and efficacy of statins
The concerns of Rory Collins and colleagues in their recent comprehensive Review1 addressing possible under use of statins, are well received. However, more than half of patients discontinue statin therapy.2 Adverse effects seem likely to contribute to this. The clinical trials discussed by Collins and colleagues were industry-sponsored and designed to show efficacy, not safety. These trials did not recruit patients who were previously intolerant of statins or who had complex comorbidities, making it inevitable that adverse effects were substantially under-represented.